MedTrace Logo

Efficacy of Ranibizumab in Combination With Photodynamic Therapy for Wet Age-Related Macular Degeneration

NCT00813891 · Status: UNKNOWN · Phase: PHASE4 · Type: INTERVENTIONAL · Enrollment: 180

Last updated 2008-12-23

No results posted yet for this study

Summary

The purpose of the investigators study is to look at the visual outcomes of Ranibizumab injections in combination with photodynamic therapy for the treatment of neovascular age-related macular degeneration.

Conditions

  • Macular Degeneration
  • Visual Acuity

Interventions

DRUG

Ranibizumab

Intraocular injection of 0.5mg of Ranibizumab one week prior to PDT with verteporfin

DRUG

Ranibizumab

Intraocular injection of 0.5mg of Ranibizumab one week after PDT with verteporfin

DRUG

Ranibizumab

Intraocular injection of 0.5mg of Ranibizumab with no accompanying PDT with verteporfin

Sponsors & Collaborators

  • McGill University Health Centre/Research Institute of the McGill University Health Centre

    lead OTHER

Principal Investigators

  • John Galic, MD · Montreal Retina Institute

  • John Chen, MD · Montreal Retina Institute

Study Design

Allocation
RANDOMIZED
Purpose
TREATMENT
Masking
SINGLE
Model
PARALLEL

Eligibility

Min Age
50 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2009-01-31
Primary Completion
2009-12-31
Completion
2009-12-31

Countries

  • Canada

Study Locations

More Related Trials

Entities

Drugs

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT00813891 on ClinicalTrials.gov